Difference between revisions of "Mogamulizumab (Poteligeo)"
Jump to navigation
Jump to search
m |
|||
| Line 10: | Line 10: | ||
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
| + | [[Category:Anti-CCR4 antibodies]] | ||
[[Category:T-cell lymphoma medications]] | [[Category:T-cell lymphoma medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
Revision as of 17:57, 26 November 2014
Mechanism of action
Defucosylated anti-cc chemokine receptor 4 (CCR4) antibody
Preliminary results
T-cell lymphoma
- Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1157-63. Epub 2014 Mar 10. link to original article PubMed